tradingkey.logo

Edwards Lifesciences Corp

EW
查看详细走势图
83.639USD
+0.559+0.67%
交易中 美东报价延迟15分钟
48.57B总市值
35.62市盈率 TTM

Edwards Lifesciences Corp

83.639
+0.559+0.67%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.67%

5天

-2.96%

1月

-3.08%

6月

+11.30%

今年开始到现在

+12.98%

1年

+14.07%

查看详细走势图

TradingKey Edwards Lifesciences Corp股票评分

单位: USD 更新时间: 2025-12-12

操作建议

Edwards Lifesciences Corp当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名17/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价94.75。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Edwards Lifesciences Corp评分

相关信息

行业排名
17 / 208
全市场排名
77 / 4592
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 34 位分析师
买入
评级
94.747
目标均价
+12.37%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Edwards Lifesciences Corp亮点

亮点风险
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
利润高增长
公司净利润处于行业前列,最新年度总收入5.44B美元
估值高估
公司最新PE估值35.38,处于3年历史高位
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值7.64K

Edwards Lifesciences Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Edwards Lifesciences Corp简介

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
公司代码EW
公司Edwards Lifesciences Corp
CEOZovighian (Bernard J)
网址https://www.edwards.com

常见问题

Edwards Lifesciences Corp(EW)的当前股价是多少?

Edwards Lifesciences Corp(EW)的当前股价是 83.639。

Edwards Lifesciences Corp的股票代码是什么?

Edwards Lifesciences Corp的股票代码是EW。

Edwards Lifesciences Corp股票的52周最高点是多少?

Edwards Lifesciences Corp股票的52周最高点是87.890。

Edwards Lifesciences Corp股票的52周最低点是多少?

Edwards Lifesciences Corp股票的52周最低点是65.940。

Edwards Lifesciences Corp的市值是多少?

Edwards Lifesciences Corp的市值是48.57B。

Edwards Lifesciences Corp的净利润是多少?

Edwards Lifesciences Corp的净利润为4.17B。

现在Edwards Lifesciences Corp(EW)的股票是买入、持有还是卖出?

根据分析师评级,Edwards Lifesciences Corp(EW)的总体评级为买入,目标价格为94.747。

Edwards Lifesciences Corp(EW)股票的每股收益(EPS TTM)是多少

Edwards Lifesciences Corp(EW)股票的每股收益(EPS TTM)是2.348。
KeyAI